BioAojing Biotech Completes Tens of Millions RMB Seed Financing with Riemann Hypothesis as Exclusive Financial Advisor
Riemann-Hypothesis
Boutique Investment Bank in the Biomedical Field
Reflecting on this round of fundraising, Dr. Li Jinling, founder of BioAging, stated, “This seed funding round was conducted during the year-end period and amidst recurring pandemic outbreaks. Its rapid and efficient completion is inseparable from our close collaboration with Riemann-Hypothesis.”
Riemann-Hypothesis demonstrated exceptional professionalism, a strong sense of responsibility, and high efficiency throughout every stage of this financing round. Leveraging its profound understanding of project financing, particularly the most challenging early-stage funding, Riemann-Hypothesis continuously refined its financing strategy, overcame numerous obstacles, and ultimately achieved a successful closing.
“Most importantly, we highly appreciate the exclusive strategic partnership and fully managed operational model established between our two parties. This arrangement has not only helped us avoid substantial trial-and-error costs associated with fundraising but also allowed us to conserve significant energy to focus on research and development. We are deeply grateful for this support and will continue to maintain a long-term strategic collaboration with Riemann-Hypothesis.”
Recently,BioAurora Biotechnology Co., Ltd.（(referred to as “BioAging” or the “Company”)—The World's OnlyCapable of achieving both“Large FragmentDNAInsertionand“Precise Insertion”gene editing technology platform,World’s Top-Tierof its rabbit mammary gland bioreactor R&D and production platform, announced the completion of a seed financing round worth tens of millions of RMB. This round was solely invested by Xinhenglida Capital,Riemann-Hypothesis served as the exclusive financial advisor for this round of financing.
Chengdu Bi’ao Jingbiotechnology Co., Ltd. was established in June 2021, with its holding company being 3H PROT BIOPHARM (hereinafter referred to as “3H”), incorporated in the Cayman Islands. The company possesses the world’s only core patented technology for TARGATT animal mammary gland bioreactors, establishing a world-class rabbit mammary gland bioreactor platform—namely, the Modernized Rabbit Pharming (MRP) platform—for the research, development, and production of protein drugs and protein products. This core technology leverages the DNA and integrase system characterized by specific recognition between bacteria and bacteriophages, enabling precise, efficient, and complete insertion of large fragments of target protein DNA (i.e., the product) into the animal genome. This technical approach addresses the key pain points and shortcomings of other protein pharmaceutical platforms, ensuring both genetic stability in animals and production consistency. Furthermore, protein expression in these animals occurs under optimal physiological conditions for growth, thereby maximizing protein yield. Meanwhile, the animal mammary gland provides an excellent natural environment for complex protein expression and post-translational modifications, laying the foundation for enhanced protein quality. The company’s TARGATT technology is a gene-editing technique that combines “large-fragment DNA” capability with “precise insertion,” endowing the MRP platform with advantages such as high efficiency, low investment, low cost, high protein yield, superior protein quality, and flexible scalability. These benefits are particularly evident in the development and production of complex proteins and high-activity protein drugs.Breakthrough AchievedBiological and manufacturing process challenges that are difficult or impossible to overcome with other platformsBottleneck, thereby demonstrating the absolute advantages of the MRP platform. Meanwhile, these strengths have been highly recognized by the investment community, enabling Bio-Ao Jing to efficiently and successfully complete its seed financing round. The funds raised in this round will be primarily allocated to platform construction and advancing the development of its existing product pipeline.
The company’s core team comprises top-tier R&D professionals from both domestic and international industry and academic sectors. On average, team members have over 15 years of experience at leading U.S. biopharmaceutical companies and more than 20 years of experience in China. Four of them have successful entrepreneurial experience in biotechnology firms. Their combined expertise in gene editing, animal models, and protein drug production spans over 100 years, providing a strong foundation for BioArct’s successful operations in China. The company’s scientific advisory team includesAcademicians of Domestic and International Academies of SciencesandIndustry Leaders, primarily engaged in virology, vaccine research and development and production, animal genetics, protein biochemistry, and the construction and management of rodent models.
Bi AojingBiologyFounder, Dr. Li JinlingStatement: We extend our deepest gratitude to the company’s strong and professional founding team for their continued efforts, and to our investors for their steadfast support and trust. The successful completion of this funding round serves as a full endorsement of BioAojing’s operational capabilities and the development potential of the MRP platform. Moving forward, guided by our noble mission to deliver care, benefit patients, improve quality of life, and enhance drug accessibility, we will strive to make MRP the most efficient recombinant protein production facility. Our vision is to achieve “high quality at affordable prices—premium but not pricey” for biologics. We are committed to building China’s first animal bioreactor platform, establishing ourselves as a respected biopharmaceutical company rooted in China and leading globally.
Zhao Yongfa, Partner at Xinhenglida Capitalstated: “We are delighted to participate in the seed-round investment of BioAojing. Compared with traditional protein production platform technologies, BioAojing’s proprietary rabbit mammary gland platform technology offers revolutionary advantages and has become relatively mature after years of technological accumulation. Once large-scale production facilities are successfully established, it is poised to reshape the landscape of the protein production industry. Leveraging its platform-based production technology, the company can concurrently develop and manufacture multiple protein product pipelines, enabling a dual strategy that encompasses both the R&D of proprietary innovative protein therapeutics and the production of existing protein products. The founding team boasts profound technical expertise and industry resources, along with extensive management experience in large-scale industrial production. This is why we are firmly confident in BioAojing’s sustained rapid growth in the future.”
As part of this round of financingExclusiveFinancial Advisor, Dr. Li Chaoxing, Chairman of Riemann-HypothesisIt stated: “BioArrow’s exclusive TARGATT-Rabbit protein production platform technology is built upon two precise gene-editing platforms: CRISPR (the 2020 Nobel Prize in Chemistry) and TARGATT. It is the world’s only gene-editing technology platform capable of achieving both ‘large-fragment DNA insertion’ and ‘precise insertion,’ boasting the world’s leading rabbit mammary gland bioreactor R&D and production platform. Compared with similar gene-editing technologies, it offers higher precision insertion efficiency, higher expression levels, and greater genetic stability. Compared with other protein production platforms, the TARGATT-Rabbit system delivers higher production efficiency, lower costs, and better quality, possessing absolute advantages lacking in other platforms. Compared with mammary gland bioreactors in other species, it is the fastest, featuring shorter gestation periods, higher milk protein content, and shorter product development cycles. In terms of benchmarking enterprises, there are few abroad with small development scales, and none domestically. The company has established a complete patent system and strong intellectual property barriers, and has developed TARGATT models in rabbits, mice, rats, pigs, cattle, sheep, and various cell lines as technical reserves, with over 3,000 application instances, more than 50% of which are humanized models. The platform’s unique technological advantages and accumulated expertise will provide BioArrow with sustained industry competitiveness.”
Shenzhen Xinhenglida Capital Management Co., Ltd. is a private equity investment fund management company registered and filed with the Asset Management Association of China (AMAC) under the supervision of the China Securities Regulatory Commission (Registration No.: P1003636). Established in Shenzhen Qianhai, part of the Shenzhen-Hong Kong Modern Services Industry Cooperation Zone, and approved by the Qianhai Authority of Shenzhen Municipality and the Shenzhen Market Supervision Administration, the company specializes in fund management, investment management, and investment consulting as its core businesses.
Shenzhen Xinhenglida Capital Management Co., Ltd. focuses its investments on the biotechnology and healthcare, advanced manufacturing, artificial intelligence, and TMT sectors. Its investment strategy primarily targets early-stage and growth-stage companies, while also considering opportunities in mature enterprises and pre-IPO projects. The investment team possesses a global perspective and comprehensive knowledge base, with deep familiarity with global technological trends, technical development directions, and financial and capital markets. With many years of experience in the venture capital industry, the team has accumulated extensive expertise, strong capabilities in enterprise valuation, and a robust risk management mindset, delivering impressive investment performance.
Shenzhen Xinhenglida Capital Management Co., Ltd. aspires to grow alongside its investors, becoming a long-term strategic partner that creates value for investors, employees, the enterprise, and society.
Riemann-Hypothesis, founded in 2018 by Dr. Li Chaoxing upon his return to China from the United States, is an integrated platform dedicated to “institutionalized” industrial innovation in the early-stage life sciences sector. Upholding its original mission of collaborating with scientist-entrepreneurs who possess global vision, profound insights, and ambitious aspirations, Riemann-Hypothesis is committed to providing early-stage investment and operational incubation for original and pioneering biomedical projects worldwide. It further develops a “fully managed,” “institutionalized” enabling incubation ecosystem, thereby breaking through the limitations of traditional technology transfer, venture capital investment, and boutique investment banking.